| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| July 23, 2026 | ±2.8% | +8.6% | under-priced |
| April 22, 2026 | ±3.0% | -0.5% | over-priced |
| October 21, 2025 | ±1.5% | -3.0% | under-priced |
| July 23, 2025 | ±2.8% | -4.3% | under-priced |
| April 23, 2025 | ±3.5% | +0.4% | over-priced |
| October 23, 2024 | ±2.7% | -0.2% | over-priced |
| July 24, 2024 | ±2.9% | +2.1% | over-priced |
| April 24, 2024 | ±2.6% | +0.6% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $2.84 | $3.0B | $334M |
| Q1 FY2026 | $2.24 | $2.9B | $264M |
| Q4 FY2025 | $2.18 | $2.8B | $256M |
| Q3 FY2025 | $2.16 | $2.8B | $259M |
Quest Diagnostics Inc. (DGX) reports in 109 days, with the next report estimated for November 14, 2026. Across the last 8 reports, options priced an average ±2.7% earnings move while the stock actually moved 2.5% on average — the market has been roughly fair on DGX's earnings risk. Fundamentals into the print: EPS up 15.0% year-over-year, revenue up 10.2%. QuantLogix's live 5-factor engine currently reads DGX as a strong buy at 93/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →